GLP-1 and Non-Alcoholic Steatohepatitis (NASH): Liver Biopsy Data from Trials
Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI
GLP-1 receptor agonists show promise in treating non-alcoholic steatohepatitis (NASH) by improving liver histology, with clinical trials demonstrating significant reductions in liver fat and inflammation, and even NASH resolution, often supported by liver biopsy data.
Non-alcoholic steatohepatitis (NASH), now increasingly referred to as metabolic dysfunction–associated steatohepatitis (MASH), represents a significant global health challenge, characterized by hepatic steatosis, inflammation, and hepatocellular ballooning, often progressing to fibrosis, cirrhosis, and hepatocellular carcinoma. The absence of approved pharmacological therapies has underscored the urgent need for effective interventions. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), initially developed for type 2 diabetes and obesity, have emerged as promising candidates due to their pleiotropic effects on metabolism and inflammation.
Semaglutide's Impact on MASH Histology: The ESSENCE Trial
Recent phase 3 clinical trials have provided compelling evidence for the efficacy of GLP-1 RAs in achieving histological improvement in MASH. A notable example is the ESSENCE trial, which investigated once-weekly subcutaneous semaglutide at a dose of 2.4 mg in patients with biopsy-defined MASH and moderate or advanced liver fibrosis (stage 2 or 3) [1].
The interim analysis of the ESSENCE trial, conducted at week 72, reported significant findings:
Resolution of Steatohepatitis: 62.9% of patients in the semaglutide group achieved resolution of steatohepatitis without worsening of liver fibrosis, compared to 34.3% in the placebo group. This represents an estimated difference of 28.7 percentage points (95% confidence interval [CI], 21.1 to 36.2; P<0.001) [1].
Reduction in Liver Fibrosis: A reduction in liver fibrosis without worsening of steatohepatitis was observed in 36.8% of patients receiving semaglutide, versus 22.4% in the placebo group. The estimated difference was 14.4 percentage points (95% CI, 7.5 to 21.3; P<0.001) [1].
Combined Endpoints: A combined endpoint of steatohepatitis resolution and fibrosis reduction was achieved by 32.7% of the semaglutide group, compared to 16.1% in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001) [1].
These results highlight semaglutide's ability to not only resolve the inflammatory and degenerative components of MASH but also to mitigate the progression of liver fibrosis, a critical factor in preventing end-stage liver disease. The mean change in body weight was also substantial, with a -10.5% reduction in the semaglutide group versus -2.0% with placebo, demonstrating the drug's potent weight-loss effects which contribute to its hepatoprotective benefits [1].
Liraglutide's Efficacy in NASH: The LEAN Trial
Another GLP-1 RA, liraglutide, has also demonstrated positive histological outcomes in MASH. The LEAN (Liraglutide Efficacy and Action in Non-alcoholic steatohepatitis) trial, a phase 2b study, showed that 48 weeks of liraglutide treatment (1.8 mg daily) led to significant improvements in liver histology [2]. Specifically, 39% of patients treated with liraglutide achieved resolution of definite NASH without worsening of fibrosis, compared to 9% in the placebo group [2]. While the LEAN trial focused on an earlier stage of development, its findings provided crucial proof-of-concept for GLP-1 RAs in MASH treatment.
Mechanisms of Action Beyond Weight Loss
The benefits of GLP-1 RAs in MASH extend beyond their well-known effects on weight loss and glycemic control. These agents exert direct and indirect effects on hepatic pathology:
Improved Insulin Sensitivity: GLP-1 RAs enhance insulin sensitivity, reducing hepatic fat accumulation and improving glucose metabolism [3].
Reduced Hepatic Lipogenesis: They can directly inhibit lipogenesis in the liver and promote fatty acid oxidation [3].
Anti-inflammatory Effects: GLP-1 RAs possess anti-inflammatory properties, reducing the inflammatory cascade within the liver that drives MASH progression [3].
Clinical Implications and Future Directions
The liver biopsy data from trials like ESSENCE and LEAN provide robust evidence supporting the use of GLP-1 RAs for MASH. The significant histological improvements observed, particularly in fibrosis reduction, represent a major step forward in the management of this complex disease. These findings are critical for clinicians considering treatment options for patients with MASH, especially those with advanced fibrosis who are at higher risk of progression to cirrhosis.
Further research is ongoing to evaluate the long-term outcomes, optimal dosing strategies, and the potential for combination therapies to maximize histological regression and prevent clinical events in MASH. The development of GLP-1 RAs marks a pivotal moment in the therapeutic landscape for MASH, offering hope for a disease that has historically lacked effective medical interventions.